Drug intelligence / Profile preview

morphine-TFCS-KLH

Development stage: Preclinical
Lead developer: Peking University
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**Morphine-TFCS-KLH** is an investigational active immunotherapy vaccine for opioid use disorder. It is a covalent conjugate consisting of a 6-glutarylmorphine hapten linked through a six-carbon TFCS linker to keyhole limpet hemocyanin. Subcutaneous vaccination in rats elicited antibodies that bound morphine, heroin, and 6-acetylmorphine, reducing peripheral drug availability and thereby attenuating opioid-induced dopaminergic and behavioral effects, including heroin-primed reinstatement of drug seeking. The program has been reported in preclinical rat studies and in a Peking University patent. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376548/))

Other names: morphine + TFCS + KLHmorphine-TFCS-KLH antigenmorphine-TFCS-KLH vaccine

Beyond the preview

Go deeper on morphine-TFCS-KLH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on morphine-TFCS-KLH.

Explore the full profile